Immunoglobulin E specific for Artemisia douglasiana pollen allergens (sIgE (Artemisia douglasiana))

Immunoglobulin E (IgE) antibodies specific for Artemisia douglasiana pollen allergens are the primary immunological mediators of allergic reactions to Douglas's sagewort, a plant native to the western United States (Gadermaier et al., 2004). These antibodies are produced by the immune system following sensitization to specific proteins within the pollen, such as homologs of the major mugwort allergen Art v 1 (WHO/IUIS Allergen Nomenclature). In sensitized individuals, these specific IgE molecules bind to high-affinity receptors (FcεRI) on the surface of mast cells and basophils. Upon subsequent inhalation of Artemisia douglasiana pollen, the allergens cross-link the receptor-bound IgE, triggering the immediate release of histamine, leukotrienes, and other inflammatory mediators (Bousquet et al., 2020). This physiological cascade results in the symptoms of seasonal allergic rhinitis, conjunctivitis, and can exacerbate allergic asthma. Therapeutic management includes the use of anti-IgE monoclonal antibodies like Omalizumab, which neutralize circulating IgE and prevent its interaction with effector cells (Genentech, 2023), as well as allergen-specific immunotherapy designed to shift the immune response toward tolerance.

Other names

Anti-Artemisia douglasiana IgEDouglas's sagewort-specific IgECalifornia mugwort-specific IgEIgE anti-Art dSpecific Immunoglobulin E to Artemisia douglasiana

Anti-IgE monoclonal antibodies, such as Omalizumab, bind to the Cε3 domain of the IgE heavy chain, which is the same site used for binding to the high-affinity IgE receptor (FcεRI) (Genentech, 2023). This sequestration of free IgE prevents it from sensitizing mast cells and basophils, thereby inhibiting the release of inflammatory mediators upon allergen exposure (Bousquet et al., 2020).